Yale researchers led by Madhav Dhodapkar, professor of hematology and immunobiology at Yale School of Medicine, showed how combining drugs that regulate the natural killer cells of the immune system with dendritic cells loaded with anti-tumor drugs may prevent the asymptomatic precursor state of multiple myeloma from progressing to a full blown case of the disease.
